Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Clinical evidence

BOND-002

29 evidence topics · 7 sources

Objective
Location and study date
Registered study dates and sites
FieldQuoted record
Study start (actual)“2015-06-02”
Primary completion (actual)“2018-08”
Study completion (actual)“2019-02”
Number of sites“This study has 17 locations”
Principal investigator“Gary Steinberg, MD”
Study design
Registered design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using durable complete response at 18 months as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
FieldQuoted record
Enrollment (actual)“66”
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary: limitations of BOND-002
  • Design: BOND-002 was a phase 2, open-label, single-arm study with no comparator arm.
  • Population: the 10-K describes the enrolled population as “a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC”. Eligibility allowed participants whose second BCG course had as few as two weekly treatments, and 19 of the 65 enrolled participants had Ta/T1 disease alongside 46 with CIS, so the population differs from the BCG-unresponsive population of BOND-003.
  • Endpoint reporting: the registered primary endpoint is durable complete response lasting 12 months or longer and assessed at 18 months. The only peer-reviewed report is an interim analysis of 45 participants that reported complete response at 6 months (47%). The final figures (40 of 65 participants, 61.5%, with complete response at any time; 30 of 46 participants, 65.2%, with CIS-containing disease) come from company filings, and no peer-reviewed report of the registered primary endpoint was identified.
  • Enrollment counts differ by source: the registry lists 66 participants enrolled, and the 10-K reports 65 enrolled per protocol, with 3 additional treated participants in the safety set.
  • Regimen: maintenance in BOND-002 was six weekly instillations at months 6, 12, and 18, a schedule that differs from the one used in BOND-003.
  • No results posted on ClinicalTrials.gov were identified.